Michael Mullan Alzheimers Research

 

The Roskamp Institute is devoted to understanding causes of and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. Based in Sarasota, Florida, the Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease.

Headed by Dr. Michael Mullan, the institute employs experienced and interdisciplinary scientists and technicians and houses state-of-the-art research labs and equipment to conduct scientific research. The quality of research performed at the institute reflects its motto: “Better science. Real discovery.”

 

Michael Mullan is a biomedical researcher of the β-amyloid protein and its relation to Alzheimer’s disease. Mullan’s Alzheimer research is well known among Biomedical Community. Dr. Mullan Alzheimer research work resulted in identifying the most widely known Swiss Mutation that is present in familial form. Transgenic Animal for Alzheimer Disease uses Swiss Mutation.

Dr. Mullan is currently the director[1] of the Roskamp Institute in Sarasota, Florida. Under Dr. Mullan’s guidelines the institute is carrying out cutting edge research in Alzheimer’s, Traumatic Brain Research, Gulf War Illness and other neuropsychiatric disorder.

 

Please visit websites to learn about Dr. Mullan Alzheimer’s Research Website:

 

 

Recent Posts

Treating Alzheimer’s disease: A New Chemical Approach

From the University of Liverpool and Callaghan Innovation in New Zealand comes a

study that local scientists have been developing; a new kind of chemical approach that will

harness the natural ability of complex sugars in the treatment Alzheimer’s disease.

 

The team of scientists produced a new library of sugars called heparan sulphates, which are known to control the proteins in the brain that cause memory loss.  This research has discovered  a way of efficiently producing heparan sulphates chemically within a lab, a major step in Alzheimer’s research because heparan sulphates have been found to  block an enzyme in the brain that creates small proteins.  The proteins this enzyme creates are are amyloid proteins, which work as building blocks to create plaque that causes the characteristic memory loss with the progression of Alzheimer’s.  Professor Jerry Turnbull from the University Institute of Integrative Biology remarked that the enzyme they are targeting with their chemically produced sugars is BACE, the enzyme responsible for the creation of amyloid protein.  BACE had proved a difficult enzyme to isolate and block despite many efforts by drug companies, but the ability to mass-produce the heparan sulphates has allowed scientists to continue and further their research of the enzyme.  Using their new chemical approach, research will continue on to test the heparan compounds which work most effectively to block the enzyme, and give off the least amount of side effects.  The creation of lab techniques that allow the production of heparan in mass and the resultant research on the sugar’s BACE enzyme blocking abilities will allow continued research, and hopefully new medications targeted at treating and slowing the progression of Alzheimer’s.

 

1) Ralf Schwörer, Olga V. Zubkova, Jeremy E. Turnbull, Peter C. Tyler. Synthesis of a Targeted Library of Heparan Sulfate Hexa-to Dodecasaccharides as Inhibitors of β-Secretase: Potential Therapeutics for Alzheimer’s Disease. Chemistry – A European Journal, 2013; 19 (21): 6817 DOI: 10.1002/chem.201204519

 

2) University of Liverpool (2013, May 29). New chemical approach to treat Alzheimer’s.ScienceDaily. Retrieved June 4, 2013, from http://www.sciencedaily.com /releases/2013/05/

130529092858.htm

By: Lauren Horne

The Roskamp Institute is a 501(c)3 research facility dedicated to translating the efforts of its qualified research staff into real-world results for those suffering from neurological diseases. To learn more about our programs and to get information about donating, visit www.rfdn.org.

  1. Alzheimer’s disease: Molecular Chain Reaction Found? Comments Off
  2. Children of Long-lived Parents: Less Risk of Cancer? Comments Off
  3. Alzheimer’s in Mice: Drug-reversible? Comments Off
  4. Triumphs in Genetic Sequencing of Human Diseases Comments Off
  5. Linked: Can Skin Cancer Lower Risk of Alzheimer’s disease? Comments Off
  6. A Promising New Alzheimer’s Drug Stops Memory Loss Comments Off
  7. Antibodies Effectively Treat Alzheimer’s-like Disease Comments Off
  8. ACE Inhibitors and Alzheimer’s Prevention Comments Off
  9. Investigational Therapy Focuses on Slowing Progression in Mild and Moderate Comments Off
  10. A Vicious Cycle of Alzheimer’s and Diabetic Hypoglicemia? Comments Off
  11. A New Drug Reverses Lost Brain Connections in Alzheimer’s Disease Comments Off
  12. Green Tea May Help Prevent Alzheimer’s Disease Comments Off
  13. Alzheimer’s Disease Progression Halted Due to Increased Protein Expression Comments Off
  14. Stem Cells Used to Grow New Neurons, Brain Repair Circuit Identified Comments Off
  15. The Effects of Parkinson’s disease Mutations Reversed within Cells Comments Off
  16. A New Study Shows Small-molecule Drug through Blood-Brain Barrier Comments Off
  17. Antidepressant May Slow Progression of Alzheimer’s Disease Comments Off
  18. Amino Acids Improve Sleep in Mice with Traumatic Brain Injury Comments Off
  19. Controlling length of mitochondria may cure Alzheimer’s diseases Comments Off
  20. Biomarker Could Aid in Revealing Alzheimer’s Early Comments Off
  21. Michael Mullan: Brain Fitness Programs – a scam ? Comments Off
  22. Dr. Michael Mullan Article Published in Herald Tribune: Dr. Michael Mullan: Volunteer to help fight Alzheimer’s Comments Off
  23. Donation Campaign – 36 hour giving challenge campaign Comments Off
  24. Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide. Comments Off
  25. Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer’s disease. Comments Off
  26. Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Bachmeier C, Mullan M, Paris D. Comments Off
  27. Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease. Comments Off
  28. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Comments Off
  29. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Comments Off
  30. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Comments Off
  31. Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid. Comments Off
  32. Flavonoids lower Alzheimer’s Aβ production via an NFκB dependent mechanism. Comments Off
  33. Roskamp Institute in Sarasota, Florida, have shown that an anatabine compound supplied by Rock Creek has beneficial effects on memory and learning in animal models of Alzheimer’s Disease. Michael Mullan, MD, Ph.D., CEO of the Roskamp Institute and his colleague, Dr. Daniel Paris, published these findings in October, 2011 in the European Journal of Pharmacology Comments Off
  34. Mike Mullan Alzheimer Researcher Comments on: Nicotine May Help Combat Memory Loss study by Dr. Newhouse Comments Off
  35. Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model. Comments Off
  36. Anatabine lowers Alzheimer’s Aβ production in vitro and in vivo Comments Off
  37. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Comments Off
  38. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. Comments Off
  39. Proteomic CNS profile of delayed cognitive impairment in mice exposed to gulf war agents. Comments Off
  40. Institute targets in on Alzheimer’s Comments Off
  41. Sarasota’s Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes Comments Off
  42. The Roskamp Institute Comments Off
  43. Roskamp Institute on Gulf War Illness Comments Off
  44. The Roskamp Institute Battles Drug Abuse Comments Off
  45. The Traumatic Brain Injury Program at the Roskamp Institute Comments Off
  46. Roskamp Institute finds one of the genetic causes for Tourettes syndrome Comments Off
  47. Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson Comments Off
  48. Dr. Mullan’s Alzheimer Research Offers Invaluable Insights On The Disease Comments Off
  49. Dr. Mullan’s Alzheimer Research Identified Various Genetic Variations Comments Off
  50. Family History of Alzheimer’s disease – what does it mean? Comments Off
  51. ß-amyloid exchage in the blood-brain barrier Comments Off
  52. Why work with Alzheimer’s disease patients? Comments Off
  53. Alzheimer’s disease drug developed at Roskamp Institute approved for key clinical trial funding in Europe Comments Off
  54. Roskamp institute studies may lead to better diagnosis Comments Off
  55. Research Highlights The Direct Causes Related To The Disease Comments Off
  56. Dr. Mullan’s Alzheimer Research Involved Studying Brain Proteins Comments Off
  57. Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers. Comments Off
  58. Mullan Alzheimer Research Institute Roskamp Institute aids high school students in genetic research Comments Off
  59. The Roskamp Institute investigates the role of anatabine in lowering Alzheimer’s Abeta levels. Comments Off
  60. Alzheimer Research Institute Headed By Dr. Michael Mullan Featured in the Sarasota Herald Tribune : Roskamp Institute research could help veterans Comments Off
  61. Dr. Mullan Alzheimer Presentation at Pines of Sarasota Comments Off
  62. Roskamp Institute Celebrated Veterans Day with a seminar by Alzheimer Researcher Dr. Michael Mullan Comments Off
  63. Alzheimer Expert Dr. Mullan’s comments on CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF) Comments Off
  64. Alzheimer Researcher Dr. Michael Mullans Note on Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Comments Off
  65. Effect of NSAIDS on cognitive ability of Alzheimer’s Patient — Comment by Alzheimer Researcher Mullan Comments Off
  66. Dr. Mullan’s Alzheimer Research Notes on NSAIDS and their effect on Alzheimers disease Comments Off
  67. Roskamp Institute Gulf War Illness research program Comments Off
  68. Event: Journal Club “Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade” Comments Off
  69. Event: Journal Club “The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease” Comments Off
  70. News:Nomination for Business/Education Partnership Award through the School District of Manatee County’s ePIE program Comments Off
  71. News:Roskamp Institute was recognized by the South East High School Technical Student association for partnering will the in a diabetes project Comments Off
  72. News: FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS Comments Off
  73. Event: Journal Club “NF-jB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis” Comments Off
  74. News Comments Off
  75. APOLIPOPROTEIN E GENOTYPE AND OXIDATIVE STRESS RESPONSE TO TRAUMATIC BRAIN INJURY Comments Off
  76. Event Journal Club:Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice Comments Off
  77. Event: Journal Club Comments Off
  78. Announcement Comments Off
  79. News:Dr Crawford will be speaking at 2nd Annual Girls S.T.E.M. Summit Comments Off
  80. Alzheimer’s beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2 Comments Off
  81. Tech Tips, #2: Making a homemade frit for fused silica columns Comments Off
  82. Do You Or Someone You Care For Suffer From Alzheimer’s Disease? Comments Off
  83. Reduction of b-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease Comments Off
  84. NEWS RELEASE:Investigational Immune Intervention Slows Brain Atrophy in Alzheimer’s Patients Comments Off
  85. Journal Club Comments Off
  86. FREE MEMORY SCREENING-Sarasota FL Comments Off
  87. Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide Comments Off
  88. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer’s disease Comments Off
  89. CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Comments Off
  90. Roskamp Institute Poster Abstract from VA Reasearch Week Comments Off
  91. Handling Unstructured Data in Biological Research and Clinical Trials Comments Off
  92. Tech Tips: Comments Off
  93. Roskamp Institute is participating in VA Research Week Activities Comments Off
  94. Roskamp Institute-LECOM collaboration Comments Off
  95. High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer’s disease patients Comments Off
  96. Journal Club: The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia Comments Off
  97. Alzheimer’s Disease Anti-Inflammatory Prevention Trial Comments Off
  98. Roskamp Institute is at Facebook! Comments Off
  99. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease Comments Off
  100. Characteristics of thein VitroVasoactivity of β-Amyloid Peptides Comments Off
  101. Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease Comments Off
  102. Cross Validation of the Montreal Cognitive Assessment in Community Dwelling Older Adults Residing in the Southeastern US Comments Off
  103. Volunteers for early detection of cognitive decline in older adults Comments Off
  104. Roskamp Institute hosted a town hall meeting for the Alzheimer’s Association. Comments Off
  105. Roskamp Institute Scientist Awarded a grant from the Alzheimers Association to investigate a novel therapeutic agent for the treatment of Alzheimer’s Disease. Comments Off
  106. Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer’s Disease. Comments Off
  107. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program Comments Off
  108. Southeast High School’s Roskamp Institute project placed first in Florida and fifth in National Technology Students Association finals Comments Off
  109. Local Researchers at Roskamp Institute to Test Investigational Gammaglobulin Treatment for Alzheimer’s Disease Comments Off
  110. World Alzheimer’s Day: Leaders Call for Early Diagnosis and Aggressive Research Comments Off
  111. Dementia in Older Women Comments Off
  112. Alzheimer’s and Blood Pressure Comments Off
  113. What do the names of Barack Obama, Hillary Clinton, and John McCain have to do with Alzheimer’s disease? Comments Off
  114. Double Amyloid Causes Memory Loss Comments Off
  115. First Critical Clinical Tests of the Amyloid Theory of Alzheimer’s Disease Comments Off
  116. Elan Vaccine and Alzheimer’s Disease Drug development Comments Off
  117. Alzheimer’s Disease Drug development Comments Off
  118. Clinical research for Alzheimer’s Disease at the Roskamp Institute Comments Off
  119. DRUG ADDICTION RESEARCH AT THE ROSKAMP INSTITUTE Comments Off
  120. Traumatic Brain Injury in the War Zone Comments Off
  121. Research On Traumatic Brain Injury At The Roskamp Institute Comments Off
  122. ABeta as Antiangiogenic drug Comments Off
  123. Roskamp Institute examines the cellular responses to biological warfare agents Comments Off
  124. Clinical Trials for Alzheimer’s Disease at the Roskamp Institute Comments Off
  125. Press release for James & Esther King Biomedical Research Program grant Comments Off
  126. Genetic manipulation of CD40L reduces Tau phosphorylation Comments Off
  127. The granulocyte macrophage-colony stimulating factor (GM-CSF) regulates amyloid production Comments Off
  128. Potent antiangiogenic motif in amyloid beta Comments Off
  129. CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF) Comments Off
  130. Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide Comments Off
  131. Effect of NSAIDS on cognitive ability of Alzheimer’s Patients Comments Off
  132. NSAIDS and their effect on Alzheimers disease Comments Off
  133. Roskamp Institute is Part of a Great Technology Cluster Comments Off
  134. Roskamp Institute Receives Lung Cancer Research Grant Comments Off
  135. Roskamp Institute Recognized for Its Beautification Efforts Comments Off
  136. Roskamp Institute Helps Florida’s Economy Comments Off
  137. Roskamp Institute Supports Moves for Greater State Funding of Biotech Research Comments Off
  138. Roskamp Institute Looking for Alzheimer’s Clinical Trial Participants Comments Off
  139. The Roskamp Institute Plans Alzheimer’s Treatment Trial Comments Off
  140. Roskamp’s Fiona Crawford to Participate in Panel Discussion Comments Off
  141. Roskamp Institute Will Host Neuroscience Doctorate Research Program Comments Off
  142. Roskamp Institute Alzheimer’s Research Validated by Independent Japanese Study Comments Off
  143. Roskamp Institute Receives Award of Appreciation Comments Off
  144. Roskamp Institute Studying Potential Usefulness of Beta-amyloid in Treating Alzheimer’s Comments Off
  145. Nilvadipine an anti-hypertensive drug, as a potential treatment for Alzheimer’s disease Comments Off
  146. Anti-hypertension Drugs and Alzheimers Comments Off
  147. Roskamp Institute’s Fiona Crawford to Moderate at Power of Women Series Comments Off
  148. Conscientious people are less prone to Alzheimer’s Comments Off
  149. The Traumatic Brain Injury Program at the Roskamp Institute Comments Off
  150. Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson Comments Off
  151. Senator Nelson Visit Roskamp Institute Comments Off
  152. Roskamp Institute Aims to Help Injured Soldiers Comments Off
  153. British Experts Question Need for Baby Scans Comments Off
  154. Chromosomes Shed New Light on Down Syndrome Comments Off
  155. Down Syndrome Patient Learning New Skills Comments Off
  156. Novartis Required to Correct Advertising Comments Off
  157. Tracking Wandering Alzheimer’s Sufferers Comments Off
  158. Alzheimer’s Caregiver Training Comments Off
  159. Attending College with Intellectual Disabilities Comments Off
  160. National Down Syndrome Society Comments Off
  161. Alzheimer’s Widow to Serve as British Government Adviser Comments Off
  162. Alzheimer’s Disease Disscusion Forum Comments Off
  163. The Roskamp Institute Is Good for Manatee County, Florida Comments Off
  164. Roskamp Institute Obesity and Diabetes Study Official Release Comments Off
  165. Roskamp Institute Study Examines Obesity Comments Off
  166. Clinical Trial Information Comments Off
  167. Sarkozy Vows to Defeat Alzheimer’s Comments Off
  168. Study: Spice can help Alzheimer’s Patients Comments Off
  169. Want a job in science research? Comments Off
  170. Roskamp Institute Tries to Improve Life of Alzheimer’s Suffers Comments Off
  171. Neuropsychology Comments Off
  172. Study: Alzheimer’s Cases May Quadruple by 2050 Comments Off
  173. Alzheimer’s Support Groups Comments Off
  174. Roskamp Celebrated 2006 World Alzheimer’s Day with Clinical Trial Lauch Comments Off
  175. Good News for Alzheimer’s Drug Comments Off
  176. Roskamp Institute Announces New Treatment Comments Off
  177. Roskamp Institute Media Coverage Comments Off
  178. The Roskamp Institute is Participating in a New Phase III MS Study Comments Off
  179. Michael Mullan Featured in Another Story Comments Off
  180. Roskamp’s Michael Mullan Interviewed by St. Petersburg Times Comments Off
  181. Sarasota’s Roskamp Institute Announces Participation in Multiple Sclerosis Study Comments Off
  182. Roskamp Institute recruiting for clinical trials Comments Off
  183. Roskamp Institute Announces New Class Of Drugs That Can Impact Alzheimer’s Disease Comments Off